SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending due to a intense regulatory dispute with the FDA ahead of an upcoming advisory committee meeting, where the company and agency are clashing over which Statistical Analysis Plan (SAP) should govern the HOPE-3 trial results. Investors are actively debating whether Capricor's defense against claims of post-hoc data manipulation will succeed, with community sentiment split between those viewing the FDA's briefing as evidence of incompetence or bias and those concerned that the statistical foundation of the trial results is fundamentally fragile.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica is surging following a strong quarterly earnings report that beat expectations on both top and bottom lines, accompanied by an upward revision of full-year guidance as demand for AI server infrastructure continues to accelerate. The community is actively discussing the stock's massive growth potential, with many investors highlighting the company's critical role in hyperscaler data center buildouts and debating the sustainability of its current momentum.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is facing significant selling pressure amid heightened market anxiety over the scale of AI infrastructure financing and potential credit risk linked to massive data center expansion projects. While some investors view the pullback as a buying opportunity given the company's central role in the AI ecosystem, the community remains divided over whether current capital-intensive AI buildouts are sustainable or if the sector is beginning to show signs of a speculative bubble.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

Amkor Technology is trending as investors react to a secondary share offering by the Kim family, while community discussions remain focused on the company's long-term potential as a critical player in the AI semiconductor packaging supply chain. Despite the price volatility, supporters continue to highlight Amkor's strategic partnerships and role in domestic advanced packaging as key drivers for future growth.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending as investors react to a significant revenue beat and a massive expansion in its contracted backlog following the latest earnings release. The community remains actively focused on the company's execution speed, potential hyperscaler partnerships, and the broader debate regarding the capital-intensive nature of data center infrastructure versus long-term recurring revenue growth.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. Its storage includes Smartstack, Gridstack Pro, Grisdtack, and Ultrastack. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Fluence Energy (FLNC) is trending as investors weigh significant backlog growth and strategic AI data center partnerships against recent insider selling activity and broader market volatility. The community remains focused on the company's ability to convert hyperscaler deals into consistent profitability, while technical analysts continue to monitor key support levels amid ongoing price swings.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is facing a pivotal moment as traders closely watch for a potential breakout above key resistance, with community sentiment largely driven by anticipation surrounding the Clarity Act and broader legislative developments. While some investors are aggressively adding positions in expectation of a significant macro cycle, others remain cautious of ongoing market volatility and the impact of geopolitical uncertainties.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific is trending due to the announcement of a major global restructuring plan through 2029, which involves significant pre-tax charges intended to optimize supply chains and reduce annual expenses. Investors are actively debating whether these cost-cutting measures, combined with the company's upcoming earnings report, will effectively offset short-term headwinds or create a long-term catalyst for growth.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is facing intense community debate as investors weigh strong earnings and massive buybacks against concerns that generative AI tools may disrupt its core creative software business. While some traders are betting on a recovery driven by its dominance in enterprise workflows, others are aggressively shorting the stock, citing analyst downgrades and fears that it will be displaced by newer, AI-native competitors.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is facing intense community speculation as investors anticipate imminent Phase 3 IZAR-1 trial results, with many actively positioning ahead of the upcoming BTIG conference. The discourse is dominated by debates over potential M&A activity, the company's trial design efficacy, and whether management will release clinical data during a standalone event or bundle it with earnings.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AstraZeneca's Rare Disease Setback Is A 'Clear Positive' For Omeros, Says This Analyst – A Look At Some Key Highlights 

Equity

H.C. Wainwright reiterated its ‘Buy’ rating on Omeros after AstraZeneca's Phase 3 setback in HSCT-TMA, saying that the outcome improves Yartemlea's competitive positioning.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER PR Newswire NEW YORK, July 23, 2026 NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz...

Omeros (OMER) is Amongst The Best Names Under $10 That Could Yield More Than 200% Return

Omeros (OMER) is Amongst The Best Names Under $10 That Could Yield More Than 200% Return...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER PR Newswire NEW YORK, July 9, 2026 NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz...

Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?

Key PointsHeartflow uses artificial intelligence to transform coronary imaging into actionable diagnostic data for heart disease...

OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Omeros Corporation (Omeros or the Company) (NASDAQ: OMER) for violations of the securities laws.The investigation focuses on whether the Company issued false...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER PR Newswire NEW YORK, July 1, 2026 NEW YORK, July 1, 2026 /PRNewswire/ -- Pomerantz...

Noteworthy Friday Option Activity: OMER, QCOM, REPL

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Omeros Corp (Symbol: OMER), where a total of 11,925 contracts have traded so far, representing approximately 1.2 million underlying shares. That amounts to about 60.6% o...

FDA Approved, Europe Unconvinced: Omeros' Stem Cell Transplant Treatment Hits Regulatory Divide

EMA rejects Omeros' Yartemlea for TA-TMA, citing insufficient efficacy data, despite FDA approval and U.S. launch.read more...

Why Is OMER Stock Falling Today?

European regulators issued a negative opinion on Yartemlea, Omeros’ therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

The Fed's July 28-29 meeting has markets debating a hold versus a hike, not a cut, with CME FedWatch pricing roughly a 65% chance of no change and rising odds of a September rate increase amid inflation running well above the 2% target. What do you expect the Fed to decide? Drop a comment with when you expect the first cut/hike to be.

What do you expect the Fed to decide at its FOMC meeting?  
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

Omeros Corp

Investors are bullish after a key competitor failed a Phase 3 trial for HSCT-TMA, strengthening the market position for Yartemlea.

Traders are closely watching upcoming milestones, including a crucial NTAP reimbursement decision and Q2 earnings, to drive stock movement.

Debate persists over the company's path to re-examination with the EMA following a recent negative opinion on the drug's approval.

Strong recent insider stock purchases are being cited by bulls as a clear vote of confidence against short-selling narratives.

Current Price	$11.34
Prev Close	$9.79
Open	$11.25
Dividend Yield	0.00%
50-Day Moving Average	$10.39
Beta	1.39
Avg. Volume	2.44M
PE Ratio	13.25

52-Week High	$17.65
52-Week Low	$3.44
Market Capitalization	$708.55M
EPS (Annual)	-$0.0528
Price to Book	-12.89
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

OMEROmeros Corp

Latest OMER News